Roche Philippines Cuts Tamiflu Price In Fight Against H1N1
This article was originally published in PharmAsia News
Executive Summary
Roche Philippines announced a price cut for its Tamiflu (oseltamivir) flu drug in the Philippines as part of an effort to ensure an adequate supply of the drug worldwide. Other antiviral drugs are expected to be lowered to compete with Roche, which said it was lowering its price to allow the drug to be more affordable for the nation to treat the H1N1 flu virus threat. The drug is not patented in the Philippines, so generics makers are free to market their own versions in the country. (Click here for more
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.